Peptides have the inherent ability to block and/or enhance signal transfers in the human body. Therapies that are peptide-based tap into the direct hard wiring of human physiology, yielding substantial and far-reaching benefits. When harnessed as active pharmaceutical ingredients, they can help treat a host of metabolic diseases, cardiovascular and heart conditions, and neurodegenerative disorders.
Drugs based on peptides offer lower toxicity, show higher specificity, and demonstrate fewer toxicology issues than small molecule drugs. The specificity of peptides has tremendous clinical value and makes them very attractive and lucrative therapeutics. Though previous development concentrated on oncology therapies, the current focus in the peptide market has broadened to include a wide range of treatments for such conditions as allergies, Parkinson’s, multiple sclerosis, and heart failure.
Progress in peptide manufacturing and implementation has made these compounds more accessible to the market in terms of cost, flexibility, and effectiveness. As a result, there has been a noticeable increase in peptide-based drug development and therapy. Frost & Sullivan, a market and technology research firm, published a recent finding that there are 40 approved peptide-based drugs in use today and approximately 400 being developed to treat ailments such as allergies, cancer, Alzheimer's, Huntington’s, and Parkinson’s diseases.
Peptides, the most basic of building blocks in physiology, continue to grow in prominence among pharmaceutical manufacturers.